Treating prediabetes in the obese: are GLP-1 analogues the answer?

Glucagon-like peptide 1 (GLP-1) analogues are increasingly recognised for their considerable clinical effects on weight loss and diabetes. Increasing evidence has shown their use can improve cardiovascular disease risk, decrease mortality, and provide other metabolic improvements. 1 Aronis KN Tsoukas MA Mantzoros CS Potential cardioprotective action of GLP-1: from bench to bedside. Metab Clin Exp. 2014; 63: 979-988 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialIn this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Full-Text PDF